hu1124
hu1124 Brand names, hu1124 Analogs
hu1124 Brand Names Mixture
- No information avaliable
hu1124 Chemical_Formula
No information avaliable
hu1124 RX_link
http://www.rxlist.com/cgi/generic3/raptiva.htm
hu1124 fda sheet
hu1124 msds (material safety sheet)
hu1124 Synthesis Reference
sequence listed in Werther WA, Gonzalez TN, O'Connor SJ, McCabe S, Chan B, Hotaling T, Champe M, Fox JA, Jardieu PM, Berman PW, Presta LG. Humanization of an anti-lymphocyte function-associated antigen (LFA)-1 monoclonal antibody and reengineering of the humanized antibody for binding to rhesus LFA-1. J Immunol. 1996 Dec 1;157(11):4986-95
hu1124 Molecular Weight
No information avaliable
hu1124 Melting Point
61 oC (FAB fragment), 71 oC (whole mAb)-Vermeer, A.W.P. & Norde, W., Biophys. J. 78:394-404 (2000).
hu1124 H2O Solubility
No information avaliable
hu1124 State
Liquid
hu1124 LogP
No information avaliable
hu1124 Dosage Forms
Solution (Subcutaneous Injection)
hu1124 Indication
For treatment of psoriasis
hu1124 Pharmacology
Lymphocyte activation and trafficking to skin play a role in the pathophysiology of chronic plaque psoriasis. In psoriatic skin, ICAM-1 cell surface expression is upregulated on endothelium and keratinocytes. Raptiva inhibits the binding of LFA-1 to the intercellular adhesion molecule-1 (ICAM-1), thereby inhibiting the adhesion of leukocytes to other cell types.
hu1124 Absorption
No information avaliable
hu1124 side effects and Toxicity
No information avaliable
hu1124 Patient Information
BIOD00074.html
hu1124 Organisms Affected
Humans and other mammals
